Table 1.
Demographic characteristics of the study participants
| Characteristics | Placebo (n = 32) | PBA (n = 32) | vitD3 (n = 31) | PBA + vitD3 (n = 32) |
|---|---|---|---|---|
| Age, years | 27.38 ± 8.65 | 27.72 ± 7.25 | 25.42 ± 8.15 | 27.16 ± 8.38 |
| Males | 20 (62.50%) | 22 (25.90%) | 21 (67.70%) | 22 (68.80%) |
| History of contacts | 10 (31.30%) | 11 (34.40%) | 6 (19.40%) | 8 (25.00%) |
| BCG given | 22 (68.8%) | 19 (59.4%) | 26 (83.90%) | 23 (71.90%) |
| Weight, kg | 44.75 ± 8.20 | 45.74 ± 8.91 | 42.91 ± 8.70 | 44.00 ± 7.89 |
| Duration of illness, days | 48.91 ± 25.42 | 50.63 ± 21.80 | 58.39 ± 26.81 | 52.47 ± 27.58 |
| Vitamin D status | ||||
| Deficient, < 30 nmol/L | 18 (56%) | 23 (71%) | 21 (67%) | 16 (50%) |
| Insufficient, 30–50 nmol/L | 10 (31.30%) | 6 (18.8%) | 5 (16.10%) | 12 (37.50%) |
| Sufficient, > 50 nmol/L | 4 (12.50%) | 3 (9.4%) | 5 (16.10%) | 4 (12.50%) |
| Baseline clinical score (25) | 6.47 ± 0.86 | 6.45 ± 1.09 | 6.27 ± 1.01 | 6.39 ± 0.96 |
| Baseline sputum smear | ||||
| < 3 acid-fast bacilli | 17 (43.10%) | 17 (43.10%) | 16 (51.60%) | 18 (56.20%) |
| > 3 acid-fast bacilli | 15 (46.90%) | 15 (46.90%) | 15 (48.40%) | 14 (43.80%) |
Data is presented as mean ± standard deviation or number with percentage in parentheses
Abbreviations: BCG Bacillus Calmette–Guérin